POINT Biopharma Global Inc., (PNT) News
Filter PNT News Items
PNT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PNT News Highlights
- PNT's 30 day story count now stands at 4.
- Over the past 23 days, the trend for PNT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about PNT are LLY, DEC and LNTH.
Latest PNT News From Around the Web
Below are the latest news stories about POINT BIOPHARMA GLOBAL INC that investors may wish to consider to help them evaluate PNT as an investment opportunity.
Lilly Completes Acquisition of POINT BiopharmaEli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. |
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate CancerPhase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS)BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA) |
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. |
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. |
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. |
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT BiopharmaEli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without intere |
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsAnnounced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion); transaction expected to close near the end of 2023INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September |
7 Healthcare Stocks That Are Poised to Become the Next UnicornsDiscover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. |
Lilly Announces Extension of Tender Offer to Acquire POINT BiopharmaEli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. |
Why Is Point Biopharma (PNT) Stock Up 84% Today?Point Biopharma stock is heading higher on Tuesday as investors react to news of Eli Lilly acquiring the shares of PNT for $12.50 each. |